AUTHORS
Dana Lee, MD, Sirui Ma, MD2, Ieeshiah Otarola, PharmD3, Mimi Lo, PharmD, BCPS, BCOP4, Pedro Luiz Lage Bodour Danielian, MD, MPH5, Faheem Nagpurwala6, Isaabella Schichter7, Stephanie Sun8, Ramkumar Balasubramaniyan, MD9, Laura Dodge10, Charalambos Andreadis, MD, MS11, Sanghee Hong, MD12, Poorva Bindal, MD13, Rushad Patell, MD14
AFFILIATIONS
1 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
2 University of San Francisco, San Francisco, California, United States
3 University of San Francisco, San Francisco, California, United States
4 University of San Francisco, San Francisco, California, United States
5 UConn Health, Farmington, Connecticut, United States
6 UMass Chan Medical School, Worcester, Massachusetts, United States
7 UMass Chan Medical School, Worcester, Massachusetts, United States
8 Duke University School of Medicine, Durham, North Carolina, United States
9 Duke University Medical Center, Durham, North Carolina, United States
10 Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States
11 University of San Francisco, San Francisco, California, United States
12 Duke Blood Cancer Center, Durham, North Carolina, United States
13 University of Massachusetts, Worcester, Massachusetts, United States
14 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
ABSTRACT
Introduction: Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of patients with relapsed or refractory hematologic malignancies. Accompanying toxicities that disrupt hemostatic homeostasis, such as cytokine release syndrome (CRS), immune effector-cell associated neurotoxicity syndrome (ICANS) and cytopenias, have been well documented. Bleeding and thrombotic complications are increasingly recognized after CAR T-cell therapy. However, accurate estimates of their incidence and associated risk factors remain limited.
Methods: We performed a multicenter retrospective cohort study of patients with hematologic malignancies treated with CAR T-cell therapy from 2016-2025 at four academic centers in the United States. Demographics, comorbidities, treatment, and outcome data were manually abstracted using harmonized instruments from CAR T-cell infusion through 180 days. Baseline was defined as the day of CAR T-cell infusion. Outcomes were venous thromboembolism (VTE) and clinically relevant bleeding (CRB), comprising major bleeding and clinically relevant nonmajor bleeding, graded according to International Society on Thrombosis and Haemostasis criteria. Cumulative incidences were estimated with death as a competing risk. Multivariable competing-risk Fine–Gray regression models identified factors associated with VTE and CRB, adjusting for demographics, disease and treatment characteristics, CRS/ICANS, anticoagulant/antiplatelet exposure, baseline laboratory parameters, and disease progression. Results are reported as subdistribution hazard ratios (sHRs) and 95% confidence intervals (CIs).
Results: The study cohort included 637 patients. Median age was 66.4 years (IQR, 58.5-71.7), 60.4% were male, and the most common malignancies were diffuse large B-cell lymphoma (45.1%) and multiple myeloma (42.2%). The most frequently administered CAR T-cell products were ciltacabtagene autoleucel (26.7%), axicabtagene ciloleucel (25.0%), and lisocabtagene maraleucel (22.1%). At the index date, 15.9% and 10.4% of patients were receiving anticoagulant and antiplatelet therapy, respectively; 16.8% had a history of VTE, including 11.5% with VTE within 1 year before CAR T-cell infusion. Following CAR T therapy, Any-grade CRS and ICANS occurred in 75.8% and 22.6% of patients, respectively, within which 3.5% were grade ≥3 CRS and 35.4% were grade ≥ 3 ICANS. At 180 days, cumulative incidences of underlying malignancy progression and mortality were 23.1% (95% CI, 19.9-26.5) and 7.1% (95% CI, 5.2-9.3), respectively.
The 180-day cumulative incidence of VTE was 6.1% (95% CI, 4.5-8.2). During follow-up, 44 patients experienced thrombotic events, including 39 (88.6%) venous events, most commonly upper-extremity DVT (31.8%), lower-extremity DVT (25.0%), and pulmonary embolism (15.9%). Median time to VTE was 31.0 days (IQR, 8.0-84.0). The 180-day cumulative incidence of CRB was 6.5% (95% CI, 4.7-8.6). A total of 40 patients developed CRB, including 13 (32.5%) major hemorrhages. The most common CRB sites were mucocutaneous (8, 20.0%) and upper gastrointestinal (7, 17.5%) bleeds, while major bleeding involved intracranial (6, 15.0%), upper gastrointestinal (4, 10.0%), retroperitoneal (2, 5.0%), and lower gastrointestinal (1, 2.5%) bleeding. Median time to CRB was 38.5 days (IQR, 14.0-99.0).
In multivariable competing-risk analysis, prior VTE was associated with a higher risk of VTE (sHR, 8.3; 95% CI, 2.3–29.3; P=0.001), whereas baseline anticoagulation was associated with a lower risk (sHR, 0.07; 95% CI, 0.01–0.4; P=0.004). Factors independently associated with CRB included grade ≥3 CRS (sHR, 12.8; 95% CI, 2.7–60.9; P=0.001), grade ≥3 ICANS (sHR, 4.3; 95% CI, 1.3–13.9; P=0.004), baseline anticoagulation (sHR, 6.6; 95% CI, 2.2–20.2; P=0.001), and disease progression during follow-up (sHR, 3.8; 95% CI, 1.8–7.9; P<0.001).
Conclusion: VTE and CRB were frequent within 180 days of CAR T-cell therapy and were associated with distinct clinical risk factors. Prior VTE was strongly associated with subsequent VTE, whereas baseline anticoagulation was associated with lower VTE risk but higher bleeding risk. Severe CRS, severe ICANS, and disease progression were also independently associated with CRB. These findings can guide individualized strategies for thromboprophylaxis, anticoagulation management, and bleeding-risk mitigation after CAR T-cell therapy.
DISCLOSURES
Dana Lee, MD: No relevant conflicts of interest to declare.